Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluzoparib + etoposide
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fluzoparib + etoposide is an investigational combination therapy being evaluated for the treatment of recurrent gynecological malignancies, including ovarian, fallopian tube, and primary peritoneal cancers. Fluzoparib is a potent, orally bioavailable small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1 and 2, which prevents DNA repair and induces synthetic lethality in cells with homologous recombination deficiencies, such as those with BRCA mutations. Etoposide is a cytotoxic chemotherapy agent that acts as a topoisomerase II inhibitor, causing DNA double-strand breaks by stabilizing the transient complex between the enzyme and DNA. The combination aims to synergistically enhance DNA damage and inhibit repair mechanisms, potentially overcoming resistance to single-agent therapies. This specific regimen is being investigated in Phase 2 clinical trials led by the Liaoning Cancer Hospital and Institute, utilizing fluzoparib developed by Jiangsu Hengrui Pharmaceuticals.
- Other names
- fluzoparib and etoposideetoposide and fluzoparib
02
Targets
PARP3 (Poly(adp-ribose) polymerase 3)PARP2 (Poly (adp-ribose) polymerase 2)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on fluzoparib + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluzoparib + etoposide.